547 related articles for article (PubMed ID: 32703131)
1. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.
Piperigkou Z; Manou D; Karamanou K; Theocharis AD
Methods Mol Biol; 2018; 1731():325-348. PubMed ID: 29318564
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview.
Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
Eur J Med Chem; 2020 May; 194():112260. PubMed ID: 32224379
[TBL] [Abstract][Full Text] [Related]
4. Physiological Properties, Functions, and Trends in the Matrix Metalloproteinase Inhibitors in Inflammation-Mediated Human Diseases.
Kim IS; Yang WS; Kim CH
Curr Med Chem; 2023; 30(18):2075-2112. PubMed ID: 36017851
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
[TBL] [Abstract][Full Text] [Related]
6. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
[TBL] [Abstract][Full Text] [Related]
7. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS; Lin CW; Su SC; Yang SF
Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: Recent progress and current challenges.
Shi Y; Ma X; Fang G; Tian X; Ge C
NanoImpact; 2021 Jan; 21():100293. PubMed ID: 35559782
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.
Chen C; Yang X; Fang H; Hou X
Eur J Med Chem; 2019 Nov; 181():111563. PubMed ID: 31415980
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies.
Das S; Amin SA; Jha T
Eur J Med Chem; 2021 Nov; 223():113623. PubMed ID: 34157437
[TBL] [Abstract][Full Text] [Related]
13. Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.
Mitsiades N; Poulaki V; Mitsiades CS; Anderson KC
Expert Opin Investig Drugs; 2001 Jun; 10(6):1075-84. PubMed ID: 11772236
[TBL] [Abstract][Full Text] [Related]
14. Status of research on matrix metalloproteinases (MMPs) in India.
Bulbule A; Saraswati S; Kundu GC
Expert Opin Ther Targets; 2011 Jun; 15(6):671-5. PubMed ID: 21476880
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs).
Li X; Wu JF
Recent Pat Anticancer Drug Discov; 2010 Jun; 5(2):109-41. PubMed ID: 19951249
[TBL] [Abstract][Full Text] [Related]
16. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.
Gialeli C; Theocharis AD; Karamanos NK
FEBS J; 2011 Jan; 278(1):16-27. PubMed ID: 21087457
[TBL] [Abstract][Full Text] [Related]
17. Next generation matrix metalloproteinase inhibitors - Novel strategies bring new prospects.
Levin M; Udi Y; Solomonov I; Sagi I
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt A):1927-1939. PubMed ID: 28636874
[TBL] [Abstract][Full Text] [Related]
18. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
Senn N; Ott M; Lanz J; Riedl R
J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
[TBL] [Abstract][Full Text] [Related]
19. Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023).
Almutairi S; Kalloush HM; Manoon NA; Bardaweel SK
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513440
[TBL] [Abstract][Full Text] [Related]
20. An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present).
Banerjee S; Baidya SK; Adhikari N; Jha T
Expert Opin Ther Pat; 2023 Oct; 33(10):631-649. PubMed ID: 37982191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]